Alvotech Snaps Up Xbrane’s R&D And Cimzia Rival For $27m

Swedish Biosimilars Developer Retains Ranibizumab And Nivolumab Assets

 
• By Dave Wallace
  
Xbrane’s R&D functions in Sweden will transfer to Alvotech (Shutterstock)

More from Deals

More from Products